Gemcitabine was shown to inactivate ribonucleotide reductase activity by interfering with RRM2 and binding to RRM1 by its diphosphate form, and therefore, has been approved for the treatment of various types of cancer including HCC [86]. Here, RRM2 is linked to hepatocellular carcinoma.